215 related articles for article (PubMed ID: 26797204)
1. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction.
Gao L; Yang L; Qian S; Li T; Han P; Yuan J
Int J Gynaecol Obstet; 2016 May; 133(2):139-45. PubMed ID: 26797204
[TBL] [Abstract][Full Text] [Related]
2. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
3. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
4. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
6. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
9. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database.
DE Nunzio C; Nacchia A; Grimaldi MC; Turchi B; Rovesti L; Franco A; Guarnotta G; Voglino O; Mancini E; Baldassarri V; Lombardo R; Cicione A; Tubaro A
Minerva Urol Nephrol; 2024 Apr; 76(2):203-209. PubMed ID: 38498298
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
[TBL] [Abstract][Full Text] [Related]
11. Testosterone supplementation and sexual function: a meta-analysis study.
Corona G; Isidori AM; Buvat J; Aversa A; Rastrelli G; Hackett G; Rochira V; Sforza A; Lenzi A; Mannucci E; Maggi M
J Sex Med; 2014 Jun; 11(6):1577-92. PubMed ID: 24697970
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
García-Perdomo HA; Echeverría-García F; Tobías A
Urol Int; 2017; 98(2):198-204. PubMed ID: 27509143
[TBL] [Abstract][Full Text] [Related]
16. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
18. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Mostafa T; Alghobary MF
Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
[TBL] [Abstract][Full Text] [Related]
19. Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
Dong L; Zhang X; Yan X; Shen Y; Yu X; Li Y
Medicine (Baltimore); 2019 Dec; 98(50):e18317. PubMed ID: 31852117
[TBL] [Abstract][Full Text] [Related]
20. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
